Klafki Hans-Wolfgang, Staufenbiel Matthias, Kornhuber Johannes, Wiltfang Jens
Department of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, Germany.
Brain. 2006 Nov;129(Pt 11):2840-55. doi: 10.1093/brain/awl280. Epub 2006 Oct 3.
Alzheimer's disease is an age-related progressive neurodegenerative disorder with an enormous unmet medical need. It is the most common form of dementia affecting approximately 5% of adults over 65 years. In view of our ageing society the number of patients, as well as the economical and social impact, is expected to grow dramatically in the future. Currently available medications appear to be able to produce moderate symptomatic benefits but not to stop disease progression. The search for novel therapeutic approaches targeting the presumed underlying pathogenic mechanisms has been a major focus of research and it is expected that novel medications with disease-modifying properties will emerge from these efforts in the future. In this review, currently available drugs as well as novel therapeutic strategies, in particular those targeting amyloid and tau pathologies, are discussed.
阿尔茨海默病是一种与年龄相关的进行性神经退行性疾病,存在巨大的未满足医疗需求。它是最常见的痴呆形式,影响约5%的65岁以上成年人。鉴于我们社会的老龄化,预计未来患者数量以及经济和社会影响将急剧增长。目前可用的药物似乎只能产生适度的症状改善,但无法阻止疾病进展。寻找针对推测的潜在致病机制的新型治疗方法一直是研究的主要重点,预计未来这些努力将产生具有疾病修饰特性的新型药物。在这篇综述中,讨论了目前可用的药物以及新型治疗策略,特别是那些针对淀粉样蛋白和tau病理的策略。